Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Hematological oncology [Hematol Oncol] NLMUID: 8307268"" wg kryterium: JN


Tytuł:
Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
Autorzy:
Sun Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.; Beijing Hightrust Diagnostics, Co., Ltd, Beijing, China.
Wang X; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Chen WM; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Hao Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Li LD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Li JY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Sun K; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Shi ZY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Jiang H; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Jiang Q; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Qin YZ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3264.
Typ publikacji:
Journal Article
MeSH Terms:
Core Binding Factor Alpha 2 Subunit*/genetics
Leukemia, Myeloid, Acute*/therapy
Humans ; Translocation, Genetic ; RUNX1 Translocation Partner 1 Protein/genetics ; Prognosis ; Recurrence ; Neoplasm, Residual/genetics ; Pathologic Complete Response
Czasopismo naukowe
Tytuł:
Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement.
Autorzy:
Abenavoli EM; Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Linguanti F; Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Anichini M; Department of Radiology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Miele V; Department of Radiology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Mungai F; Department of Radiology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Palazzo M; Hematology Department, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Nassi L; Hematology Department, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Puccini B; Hematology Department, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Romano I; Hematology Department, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Sordi B; Hematology Department, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Sciagrà R; Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Simontacchi G; Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Vannucchi AM; Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Berti V; Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3261.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Positron Emission Tomography Computed Tomography*/methods
Hodgkin Disease*/diagnostic imaging
Hodgkin Disease*/drug therapy
Humans ; Fluorodeoxyglucose F18/therapeutic use ; Positron-Emission Tomography ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model.
Autorzy:
Romeo MA; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Focaccetti C; Department of Clinical Sciences and Translational Medicine, 'Tor Vergata' University of Rome, Rome, Italy.
Arena A; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Benedetti R; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Di Crosta M; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Palumbo C; Department of Clinical Sciences and Translational Medicine, 'Tor Vergata' University of Rome, Rome, Italy.
Gilardini Montani MS; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Santarelli R; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Gonnella R; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
D'Orazi G; Department of Neurosciences, Imaging and Clinical Sciences, University G. D'Annunzio, Chieti, Italy.
Bei R; Department of Clinical Sciences and Translational Medicine, 'Tor Vergata' University of Rome, Rome, Italy.
Cirone M; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3262.
Typ publikacji:
Letter
MeSH Terms:
Lymphoma, Primary Effusion*/drug therapy
Antineoplastic Agents*/adverse effects
Humans ; Animals ; Mice ; Bortezomib/pharmacology
Opinia redakcyjna
Tytuł:
The role of baseline 2-[ F]-FDG-PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis.
Autorzy:
Albano D; Nuclear Medicine, ASST Spedali Civili Brescia, Brescia, Italy.; Nuclear Medicine, University of Brescia, Brescia, Italy.
Calabrò A; Nuclear Medicine, ASST Spedali Civili Brescia, Brescia, Italy.; Nuclear Medicine, University of Brescia, Brescia, Italy.
Dondi F; Nuclear Medicine, ASST Spedali Civili Brescia, Brescia, Italy.; Nuclear Medicine, University of Brescia, Brescia, Italy.
Bagnasco S; Division of Hematology, ASST Spedali Civili Brescia, Brescia, Italy.
Tucci A; Division of Hematology, ASST Spedali Civili Brescia, Brescia, Italy.
Bertagna F; Nuclear Medicine, ASST Spedali Civili Brescia, Brescia, Italy.; Nuclear Medicine, University of Brescia, Brescia, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3266.
Typ publikacji:
Journal Article
MeSH Terms:
Positron Emission Tomography Computed Tomography*
Lymphoma, B-Cell, Marginal Zone*
Lymphoma, Non-Hodgkin*
Organothiophosphorus Compounds*
Stomach Neoplasms*
Humans ; Fluorodeoxyglucose F18 ; Radiomics ; Retrospective Studies
SCR Disease Name:
Familial primary gastric lymphoma
Czasopismo naukowe
Tytuł:
Mortality associated to hematological malignancies across pandemic waves in 2020: A nationwide analysis of multiple causes of death in Italy.
Autorzy:
Grande E; Integrated System for Health, Social Assistance and Welfare, National Institute of Statistics, Rome, Italy.
Grippo F; Integrated System for Health, Social Assistance and Welfare, National Institute of Statistics, Rome, Italy.
Barbiellini Amidei C; Epidemiological Department, Azienda Zero, Padova, Italy.
Fedeli U; Epidemiological Department, Azienda Zero, Padova, Italy.
Tosetto A; Hematology Department, San Bortolo Hospital, Vicenza, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3263.
Typ publikacji:
Letter
MeSH Terms:
Pandemics*
Hematologic Neoplasms*/epidemiology
Hematologic Neoplasms*/pathology
Humans ; Cause of Death ; Italy/epidemiology
Opinia redakcyjna
Tytuł:
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis.
Autorzy:
Wang R; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.
Zhang Y; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Chang J; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.
Wang H; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Lou Y; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Yang M; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Xu G; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Tong H; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Xie W; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Zhou; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Wei J; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Mai W; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Ye X; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Meng H; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Jin J; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.
Zhu HH; Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.; Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, Zhejiang, China.; Liangzhu Laboratory, Zhejiang University, Hangzhou, Zhejiang, China.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3260.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Sulfonamides*
Bridged Bicyclo Compounds, Heterocyclic*
Young Adult ; Humans ; Propensity Score ; Daunorubicin ; Cytarabine ; Pathologic Complete Response
Czasopismo naukowe
Tytuł:
Antibody targeting of surface P-selectin glycoprotein ligand 1 leads to lymphoma apoptosis and tumorigenesis inhibition.
Autorzy:
Pereira JL; i3S-Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Porto, Portugal.; IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.; FMUP-Faculty of Medicine of the University of Porto, Porto, Portugal.
Ferreira F; i3S-Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Porto, Portugal.; IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.; Master´s degree in Bioengineering, ICBAS-Instituto de Ciências Biomédicas de Abel Salazar and Faculty of Engineering, University of Porto, Porto, Portugal.
Dos Santos NR; i3S-Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Porto, Portugal.; IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3257.
Typ publikacji:
Journal Article
MeSH Terms:
Lymphoma, T-Cell, Cutaneous*
Skin Neoplasms*
Humans ; Animals ; Mice ; P-Selectin ; Ligands ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Apoptosis ; Carcinogenesis
Czasopismo naukowe
Tytuł:
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?
Autorzy:
Duminuco A; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.; Division of Hematology and BMT Unit, A.O.U. Policlinico 'G.Rodolico-San Marco', Catania, Italy.
Nardo A; Division of Hematology and BMT Unit, A.O.U. Policlinico 'G.Rodolico-San Marco', Catania, Italy.
Palumbo GA; Division of Hematology and BMT Unit, A.O.U. Policlinico 'G.Rodolico-San Marco', Catania, Italy.; Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate 'G.F. Ingrassia', University of Catania, Catania, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3259.
Typ publikacji:
Letter
MeSH Terms:
Lymphoproliferative Disorders*/drug therapy
Nitriles*
Pyrazoles*
Pyrimidines*
Humans
Opinia redakcyjna
Tytuł:
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Autorzy:
Facon T; Department of Hematology, Lille University Hospital, Lille, France.
Moreau P; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Špicka I; Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.
Suzuki K; Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.
Yong K; Department of Haematology, University College Hospital, London, UK.
Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA.
Fukao T; Sanofi, Global Oncology, Cambridge, Massachusetts, USA.
Bisht K; Sanofi, Global Oncology, Cambridge, Massachusetts, USA.
Armstrong NM; Sanofi, Global Medical Affairs, Cambridge, Massachusetts, USA.
Macé S; Sanofi, Research and Development, Chilly-Mazarin, France.
Risse ML; Sanofi, Research and Development, Vitry-Sur-Seine, France.
Martin T; University of California San Francisco Medical Center, San Francisco, California, USA.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3258.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*
Oligopeptides*
Antibodies, Monoclonal, Humanized*
Humans ; Dexamethasone/therapeutic use ; Chromosome Aberrations ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
Autorzy:
Wang LY; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Li Y; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Jiang Q; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Jiang H; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Wang Y; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Xu LP; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Zhang XH; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Liu KY; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Tang FF; Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3256.
Typ publikacji:
Journal Article
MeSH Terms:
Core Binding Factor Alpha 2 Subunit*/genetics
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Humans ; Middle Aged ; Mutation ; Nucleophosmin ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel.
Autorzy:
Mauro FR; Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Roma, Italy.
Tedeschi A; Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
Varettoni M; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Zaja F; Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Università degli Studi di Trieste, Trieste, Italy.; Unità Complessa Operativa (UCO) Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
Barosi G; Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Mar; Vol. 42 (2), pp. e3255.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Piperidines*
Humans ; Consensus ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Tytuł:
Prognostic value of the second revision of the international staging system (R2-ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Autorzy:
Kikuchi T; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Tsukada N; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Kunisada K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Yogo M; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Oda Y; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Sato K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Takei T; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Ogura M; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Abe Y; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Suzuki K; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Ishida T; Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3248.
Typ publikacji:
Letter
MeSH Terms:
Multiple Myeloma*/therapy
Multiple Myeloma*/pathology
Hematopoietic Stem Cell Transplantation*
Humans ; Prognosis ; Neoplasm Staging ; Transplantation, Autologous ; Retrospective Studies
Opinia redakcyjna
Tytuł:
Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma.
Autorzy:
Picardi M; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
Giordano C; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
Pugliese N; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
Mascolo M; Department of Advanced Biomedical Sciences, Federico II University Medical School, Naples, Italy.
Varricchio S; Department of Advanced Biomedical Sciences, Federico II University Medical School, Naples, Italy.
Troncone G; Department of Public Health, Federico II University Medical School Naples, Naples, Italy.
Vigliar E; Department of Public Health, Federico II University Medical School Naples, Naples, Italy.
Bellavicine C; Department of Public Health, Federico II University Medical School Naples, Naples, Italy.
Lamagna M; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
Lisi D; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
Vincenzi A; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
Pane F; Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3247.
Typ publikacji:
Letter
MeSH Terms:
Lymphoma, B-Cell*/pathology
Mediastinal Neoplasms*/pathology
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/pathology
Humans ; Doxorubicin/therapeutic use ; Polyethylene Glycols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Opinia redakcyjna
Tytuł:
ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.
Autorzy:
Shi ZY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Wang X; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Chen WM; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Li LD; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Hao Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Li JY; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Sun K; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Zhao XS; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Jiang H; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Jiang Q; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Qin YZ; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3251.
Typ publikacji:
Journal Article
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Hematopoietic Stem Cell Transplantation*
Adult ; Humans ; Prognosis ; Transcription Factors ; Neoplasm, Residual/diagnosis ; Recurrence ; Trans-Activators/metabolism ; Trans-Activators/therapeutic use
Czasopismo naukowe
Tytuł:
Diagnosis of chronic B-cell lymphoproliferative disease in peripheral blood = how machine learning may help to the interpretation of flow cytometry data.
Autorzy:
Gross Z; Service clinique d'hématologie, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Pierre-Bénite, France.
Veyrat-Masson R; Laboratoire d'hématologie, CHU ESTAING, Clermont Ferrand, France.
Grange B; Laboratoire d'hématologie spécialisée, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Pierre-Bénite, France.; Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie (CIRI) INSERM U1111 - CNRS UMR5308, Lyon, France.
Huet S; Laboratoire d'hématologie spécialisée, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Pierre-Bénite, France.; Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie (CIRI) INSERM U1111 - CNRS UMR5308, Lyon, France.
Verney A; Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie (CIRI) INSERM U1111 - CNRS UMR5308, Lyon, France.
Traverse-Glehen A; Service d'anatomie-pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Pierre-Bénite, France.; INSERM U1245, Centre Henri Becquerel, UNIROUEN, University of Normandie, Rouen, France.
Ruminy P; INSERM U1245, Centre Henri Becquerel, UNIROUEN, University of Normandie, Rouen, France.
Baseggio L; Laboratoire d'hématologie spécialisée, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon, Pierre-Bénite, France.; Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie (CIRI) INSERM U1111 - CNRS UMR5308, Lyon, France.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3245.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Lymphoma, Follicular*/pathology
Humans ; Adult ; Flow Cytometry/methods ; Immunophenotyping ; B-Lymphocytes/pathology
Czasopismo naukowe
Tytuł:
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Autorzy:
Martino EA; Hematology Unit, AO Cosenza, Cosenza, Italy.
Mauro FR; Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
Reda G; Hematology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Laurenti L; Dipartimento Scienze Radiologiche ed Ematologiche, Divisione di Ematologia Fondazione Policlinico universitario A Gemelli, Rome, Italy.
Visentin A; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
Frustaci A; Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Vigna E; Hematology Unit, AO Cosenza, Cosenza, Italy.
Pepe S; Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
Catania G; A.O.N. SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
Loseto G; IRCCS Oncologico di Bari, Bari, Italy.
Murru R; Hematology and Stem Cell Transplantation Unit, Ospedale A. Businco, ARNAS G. Brotzu, Cagliari, Italy.
Chiarenza A; Divisione di Ematologia, A.O.U. Policlinico, PO G.Rodolico, Catania, Italy.
Sportoletti P; Centro di Ricerca Emato-Oncologica (CREO), Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.
Del Principe MI; Ematologia, Dipartimento di Biomedicina e Prevenzione, Università degli Studi di Roma 'Tor Vergata,' Rome, Rome, Italy.
Laureana R; Ematologia, Dipartimento di Biomedicina e Prevenzione, Università degli Studi di Roma 'Tor Vergata,' Rome, Rome, Italy.
Coscia M; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Galimberti S; Hematology, University of Pisa, Pisa, Italy.
Ferretti E; Clinical Trials Center Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Zucchetto A; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Bomben R; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Polesel J; Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Tedeschi A; Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Rossi D; Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.
Trentin L; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
Neri A; Scientific Directorate, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
Morabito F; Biotechnology Research Unit, Cosenza, Italy.
Gattei V; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Gentile M; Hematology Unit, AO Cosenza, Cosenza, Italy.; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3249.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Adenine*/analogs & derivatives
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Piperidines*
Aged, 80 and over ; Humans ; Italy ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Skeletal muscle index impacts the treatment outcome of elderly patients with diffuse large B cell lymphoma.
Autorzy:
Niiyama-Uchibori Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Okamoto H; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Miyashita A; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Mizuhara K; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kanayama-Kawaji Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Fujino T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tsukamoto T; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Mizutani S; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shimura Y; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.; Department of Blood Transfusion, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Teramukai S; Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kuroda J; Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3252.
Typ publikacji:
Journal Article
MeSH Terms:
Sarcopenia*/etiology
Sarcopenia*/diagnosis
Sarcopenia*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/complications
Lymphoma, Large B-Cell, Diffuse*/diagnosis
Lymphoma, Large B-Cell, Diffuse*/therapy
Male ; Female ; Humans ; Aged ; Aged, 80 and over ; Rituximab/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Retrospective Studies ; Cyclophosphamide/adverse effects ; Treatment Outcome ; Prognosis ; Muscle, Skeletal/diagnostic imaging ; Muscle, Skeletal/pathology
Czasopismo naukowe
Tytuł:
Possible effects of plasminogen activator inhibitor-1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides.
Autorzy:
Fujimura T; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ohuchi K; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ikawa T; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kambayashi Y; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Amagai R; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Furudate S; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Asano Y; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3244.
Typ publikacji:
Journal Article
MeSH Terms:
Mycosis Fungoides*/drug therapy
Mycosis Fungoides*/pathology
Skin Neoplasms*/drug therapy
Skin Neoplasms*/pathology
Humans ; Angiogenesis ; Bexarotene ; Endothelial Cells/metabolism ; Endothelial Cells/pathology ; Matrix Metalloproteinase 9 ; Plasminogen Activator Inhibitor 1
Czasopismo naukowe
Tytuł:
Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario.
Autorzy:
Pinto A; Department of Hematology and Developmental Therapeutics, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy.
Ladetto M; Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Martelli M; Department of Translational and Precision Medicine, Sapienza University Rome, Rome, Italy.
Visco C; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
Zaja F; Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Guardalben E; Eli Lilly Italy S.p.A., Medical Affairs, Sesto Fiorentino, Italy.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3246.
Typ publikacji:
Letter
MeSH Terms:
Lymphoma, Mantle-Cell*/drug therapy
Lymphoma, Mantle-Cell*/pathology
Antineoplastic Agents*/therapeutic use
Adult ; Humans ; Tyrosine Kinase Inhibitors ; Agammaglobulinaemia Tyrosine Kinase ; Italy ; Protein Kinase Inhibitors/adverse effects
Opinia redakcyjna
Tytuł:
Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation.
Autorzy:
Cao Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zheng X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zhang H; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Wang M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Guo W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Chen X; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Zhai W; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Wei J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Yang D; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Huang Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Pang A; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Feng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Jiang E; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Han M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Pokaż więcej
Źródło:
Hematological oncology [Hematol Oncol] 2024 Jan; Vol. 42 (1), pp. e3232. Date of Electronic Publication: 2023 Oct 04.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Hematopoietic Stem Cell Transplantation*
Humans ; Azacitidine/therapeutic use ; Prospective Studies ; Transplantation, Homologous ; Chronic Disease ; Recurrence ; Retrospective Studies
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies